Loading
A phase 1/2 trial of ICP-723 in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT04685226 by Beijing InnoCare Pharma Tech Co., Ltd., with 310 participants planned, started 2020-09-27 and due to reach its primary completion in 2028-01-25. Interventions recorded: ICP-723.
Shares InnoCare Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.